193 related articles for article (PubMed ID: 37010571)
21. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.
Molavi O; Ma Z; Mahmud A; Alshamsan A; Samuel J; Lai R; Kwon GS; Lavasanifar A
Int J Pharm; 2008 Jan; 347(1-2):118-27. PubMed ID: 17681440
[TBL] [Abstract][Full Text] [Related]
22. Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK/STAT3, MAPK/ERK, and AKT/mTOR signaling pathways in HepG2 cell line.
Üremiş N; Üremiş MM; Çiğremiş Y; Tosun E; Baysar A; Türköz Y
J Food Biochem; 2022 Oct; 46(10):e14333. PubMed ID: 35866877
[TBL] [Abstract][Full Text] [Related]
23. The cucurbitacins D, E, and I from
Jafargholizadeh N; Zargar SJ; Aftabi Y
Iran J Basic Med Sci; 2018 Mar; 21(3):253-259. PubMed ID: 29511491
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma.
Liu T; Zhang M; Zhang H; Sun C; Deng Y
Eur Arch Otorhinolaryngol; 2008 Oct; 265(10):1225-32. PubMed ID: 18309509
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacins as Anticancer Agents: A Patent Review.
Hussain H; Green IR; Saleem M; Khattak KF; Irshad M; Ali M
Recent Pat Anticancer Drug Discov; 2019; 14(2):133-143. PubMed ID: 30451116
[TBL] [Abstract][Full Text] [Related]
26. The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver.
Abbas S; Vincourt JB; Habib L; Netter P; Greige-Gerges H; Magdalou J
Toxicol Lett; 2013 Feb; 216(2-3):189-99. PubMed ID: 23194827
[TBL] [Abstract][Full Text] [Related]
27. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer.
Chen X; Bao J; Guo J; Ding Q; Lu J; Huang M; Wang Y
Anticancer Drugs; 2012 Sep; 23(8):777-87. PubMed ID: 22561419
[TBL] [Abstract][Full Text] [Related]
28. Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Henrich CJ; Thomas CL; Brooks AD; Booth NL; Lowery EM; Pompei RJ; McMahon JB; Sayers TJ
Apoptosis; 2012 Jan; 17(1):79-89. PubMed ID: 21928090
[TBL] [Abstract][Full Text] [Related]
29. Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/β-catenin signaling.
Feng H; Zang L; Zhao ZX; Kan QC
Cancer Biother Radiopharm; 2014 Jun; 29(5):210-4. PubMed ID: 24885795
[TBL] [Abstract][Full Text] [Related]
30. Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms.
Varela C; Melim C; Neves BG; Sharifi-Rad J; Calina D; Mamurova A; Cabral C
J Transl Med; 2022 Dec; 20(1):630. PubMed ID: 36585670
[TBL] [Abstract][Full Text] [Related]
31. Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway.
Liang Y; Zhang T; Ren L; Jing S; Li Z; Zuo P; Li T; Wang Y; Zhang J; Wei Z
Environ Toxicol Pharmacol; 2021 Jan; 81():103542. PubMed ID: 33161110
[TBL] [Abstract][Full Text] [Related]
32. The Determination of Molecular and Toxicological Mechanisms of Cucurbitacin E in Model Organism
Tunçbilek A; Azarkan SY; Ercan F
Curr Comput Aided Drug Des; 2023; 19(2):81-93. PubMed ID: 36321227
[TBL] [Abstract][Full Text] [Related]
33. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
Chen YW; Chen KH; Huang PI; Chen YC; Chiou GY; Lo WL; Tseng LM; Hsu HS; Chang KW; Chiou SH
Mol Cancer Ther; 2010 Nov; 9(11):2879-92. PubMed ID: 21062915
[TBL] [Abstract][Full Text] [Related]
34. Cucurbitacins attenuate microglial activation and protect from neuroinflammatory injury through Nrf2/ARE activation and STAT/NF-κB inhibition.
Park SY; Kim YH; Park G
Neurosci Lett; 2015 Nov; 609():129-36. PubMed ID: 26472707
[TBL] [Abstract][Full Text] [Related]
35. Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation.
Ren S; Ouyang DY; Saltis M; Xu LH; Zha QB; Cai JY; He XH
Cancer Chemother Pharmacol; 2012 Sep; 70(3):415-24. PubMed ID: 22814677
[TBL] [Abstract][Full Text] [Related]
36. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia.
Ding N; Yamashita U; Matsuoka H; Sugiura T; Tsukada J; Noguchi J; Yoshida Y
Cancer; 2011 Jun; 117(12):2735-46. PubMed ID: 21656752
[TBL] [Abstract][Full Text] [Related]
38. Cucurbitacin-B inhibits cancer cell migration by targeting mortalin and HDM2: computational and
Huifu H; Shefrin S; Yang S; Zhang Z; Kaul SC; Sundar D; Wadhwa R
J Biomol Struct Dyn; 2024 Mar; 42(5):2643-2652. PubMed ID: 37129211
[TBL] [Abstract][Full Text] [Related]
39. Betulin terpenoid targets OVCAR-3 human ovarian carcinoma cells by inducing mitochondrial mediated apoptosis, G2/M phase cell cycle arrest, inhibition of cell migration and invasion and modulating mTOR/PI3K/AKT signalling pathway.
Yang Q; Fei Z; Huang C
Cell Mol Biol (Noisy-le-grand); 2021 Sep; 67(2):14-19. PubMed ID: 34817343
[TBL] [Abstract][Full Text] [Related]
40. Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer.
Kim HJ; Park JH; Kim JK
Chem Biol Interact; 2014 Aug; 219():1-8. PubMed ID: 24858077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
